886502-19-8

Basic information

• Product Name: 6-CHLORO-2-FLUORO-3-METHYLBENZONITRILE
• Synonyms: 6-CHLORO-2-FLUORO-3-METHYLBENZONITRILE
• CAS NO: 886502-19-8
• Molecular Formula: C8H5ClFN
• Molecular Weight: 169.58
• Mol File: 886502-19-8.mol

Chemical Properties

• Melting Point: 56-58℃
• Boiling Point: 256.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.28±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 6-CHLORO-2-FLUORO-3-METHYLBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-2-FLUORO-3-METHYLBENZONITRILE(886502-19-8)
• EPA Substance Registry System: 6-CHLORO-2-FLUORO-3-METHYLBENZONITRILE(886502-19-8)

Safety Data

• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 886502-19-8(Hazardous Substances Data)

Usage

Nitrile derivative

Contains a nitrile functional group

Substitutions on benzene ring

Chloro and fluoro substitutions

Methyl group

Located at the 3-position on the benzene ring

Common uses

Intermediate in pharmaceutical and agrochemical synthesis

Research and development

Used in medicinal chemistry studies

Versatile building block

Can be used to create novel compounds

Therapeutic applications

Potential for creating new pharmaceuticals

Agricultural applications

Potential for creating new agrochemicals

Upstream product

• 452-75-5 4-chloro-2-fluorotoluene 
• 286474-59-7 6-chloro-2-fluoro-3-methylbenzaldehyde 

Relevant articles and documents

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.